Cargando…
Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980572/ https://www.ncbi.nlm.nih.gov/pubmed/31978161 http://dx.doi.org/10.1371/journal.pone.0228153 |
_version_ | 1783490967683203072 |
---|---|
author | Wray, Robin Wang, Junmei Iscla, Irene Blount, Paul |
author_facet | Wray, Robin Wang, Junmei Iscla, Irene Blount, Paul |
author_sort | Wray, Robin |
collection | PubMed |
description | The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways. |
format | Online Article Text |
id | pubmed-6980572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69805722020-02-04 Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site Wray, Robin Wang, Junmei Iscla, Irene Blount, Paul PLoS One Research Article The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways. Public Library of Science 2020-01-24 /pmc/articles/PMC6980572/ /pubmed/31978161 http://dx.doi.org/10.1371/journal.pone.0228153 Text en © 2020 Wray et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wray, Robin Wang, Junmei Iscla, Irene Blount, Paul Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title | Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title_full | Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title_fullStr | Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title_full_unstemmed | Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title_short | Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
title_sort | novel mscl agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980572/ https://www.ncbi.nlm.nih.gov/pubmed/31978161 http://dx.doi.org/10.1371/journal.pone.0228153 |
work_keys_str_mv | AT wrayrobin novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite AT wangjunmei novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite AT isclairene novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite AT blountpaul novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite |